GeneDx Holdings WGS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $442.68M+3.5% | $427.54M+6.3% | $402.19M+11.0% | $362.32M+9.7% | $330.14M+8.1% | ||
| $134.77M+4.2% | $129.37M+6.0% | $122.08M+2.7% | $118.91M+3.7% | $114.68M+3.3% | ||
| $307.91M+3.3% | $298.17M+6.4% | $280.11M+15.1% | $243.41M+13.0% | $215.46M+10.8% | ||
| 69.6%-0.2pp | 69.7%+0.1pp | 69.6%+2.5pp | 67.2%+1.9pp | 65.3%+1.6pp | ||
| $79.25M+10.0% | $72.03M+21.9% | $59.07M+16.0% | $50.91M+8.9% | $46.73M+2.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| -$2.62M-3.0% | -$2.54M+6.6% | -$2.72M+9.4% | -$3M+2.5% | -$3.08M-1.4% | ||
| -$11.48M-42.4% | -$8.06M-8.1% | -$7.46M-91.3% | -$3.9M+83.9% | -$24.29M+17.4% | ||
| —— | —— | —— | —— | —— | ||
| -$77.81M-270% | -$21.02M— | —— | —— | —— | ||
| -17.6%-12.7pp | -4.9%— | —— | —— | —— | ||
| -$2.66-264% | -$0.73— | —— | —— | —— | ||
| 116.5M+1.0% | 115.3M+1.5% | 113.6M+1.5% | 111.9M+2.9% | 108.8M+2.0% | ||
| 115.4M+1.0% | 114.2M+1.6% | 112.4M+1.5% | 110.7M+1.8% | 108.8M+2.0% | ||
| -$2.62M-3.0% | -$2.54M+6.6% | -$2.72M+9.4% | -$3M+2.5% | -$3.08M-1.4% | ||
| —— | —— | -$4.3M-142% | -$1.78M+78.7% | -$8.37M+37.4% | ||
| -$78.03M-273% | -$20.92M— | —— | —— | —— | ||
| $72.9M+51.8% | $48.03M-14.0% | $55.86M-5.4% | $59.06M+1.3% | $58.32M+32.1% | ||
| -$69.36M-12.8% | -$61.52M-20.7% | -$50.96M+5.7% | -$54.03M-33.8% | -$40.38M-34.0% | ||
| -$6.22M-117% | $36.37M+9.6% | $33.19M+155% | $13.02M+785% | -$1.9M+93.3% | ||
| —— | —— | —— | —— | —— | ||
| $442.68M+3.5% | $427.54M+6.3% | $402.19M+11.0% | $362.32M+9.7% | $330.14M+8.1% | ||
| -$39.64M-426% | $12.15M— | —— | —— | —— | ||
| -9%-11.8pp | 2.8%— | —— | —— | —— | ||
| -$66M-405% | -$13.08M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is GeneDx Holdings's revenue?
- GeneDx Holdings (WGS) generated $442.7M in revenue over the trailing twelve months, up 34.1% year over year.
- Is GeneDx Holdings profitable?
- GeneDx Holdings is not currently profitable: it reported a net loss of $77.8M over the trailing twelve months, a -17.6% net margin.
- What are GeneDx Holdings's profit margins?
- Gross margin is 69.6% and operating margin is -14.9%, with a -17.6% net margin.
- What is GeneDx Holdings's earnings per share?
- GeneDx Holdings's diluted EPS over the trailing twelve months is $-2.68.
- Where does GeneDx Holdings's income statement data come from?
- Every line is extracted from GeneDx Holdings's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
